HER-2 binding antagonists

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S300000, C530S350000, C530S388100, C530S388220, C424S130100, C424S141100, C424S143100

Reexamination Certificate

active

07393823

ABSTRACT:
There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO. 1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 with an affinity binding constant of at least 108M−1, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO. 2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and a pharmaceutically acceptable carrier.

REFERENCES:
patent: 4933294 (1990-06-01), Waterfield et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5464751 (1995-11-01), Greene et al.
patent: 5514554 (1996-05-01), Bacus
patent: 5571894 (1996-11-01), Wels et al.
patent: 5578482 (1996-11-01), Lippman et al.
patent: 5604107 (1997-02-01), Carney et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5705157 (1998-01-01), Greene et al.
patent: 5720937 (1998-02-01), Hudziak et al.
patent: 5747261 (1998-05-01), King et al.
patent: 5756456 (1998-05-01), Ho et al.
patent: 5763213 (1998-06-01), Ho et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5811098 (1998-09-01), Plowman et al.
patent: 5837523 (1998-11-01), Greene et al.
patent: 5861301 (1999-01-01), Terman et al.
patent: 5874528 (1999-02-01), Lupu et al.
patent: 5910583 (1999-06-01), Marks et al.
patent: 5919764 (1999-07-01), Greene et al.
patent: 5985553 (1999-11-01), King et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6020306 (2000-02-01), Boyd et al.
patent: 6045797 (2000-04-01), Margolis et al.
patent: 6054561 (2000-04-01), Ring
patent: 6166082 (2000-12-01), Kluender et al.
patent: 6174889 (2001-01-01), Cockerill et al.
patent: 6204011 (2001-03-01), Kendall et al.
patent: 6267958 (2001-07-01), Andya et al.
patent: 6333169 (2001-12-01), Hudziak et al.
patent: 6359115 (2002-03-01), Kendall et al.
patent: 6375929 (2002-04-01), Thomas, Jr. et al.
patent: 6387371 (2002-05-01), Hudziak et al.
patent: 6399063 (2002-06-01), Hudziak et al.
patent: 6399743 (2002-06-01), Majumdar
patent: 6414130 (2002-07-01), Doherty et al.
patent: 6417168 (2002-07-01), Greene et al.
patent: 6441143 (2002-08-01), Koski
patent: 6541214 (2003-04-01), Clinton et al.
patent: 2001/0014326 (2001-08-01), Andya et al.
patent: 2001/0021505 (2001-09-01), Morris et al.
patent: 2002/0146420 (2002-10-01), Bennett et al.
patent: 2002/0155527 (2002-10-01), Stuart et al.
patent: 2002/0165293 (2002-11-01), Greene et al.
patent: 2002/0172984 (2002-11-01), Holland et al.
patent: 2003/0036179 (2003-02-01), Baker et al.
patent: 2003/0044842 (2003-03-01), Desnoyers et al.
patent: 2003/0044945 (2003-03-01), Baker et al.
patent: 2003/0055239 (2003-03-01), Kendall et al.
patent: 2003/0059863 (2003-03-01), Clinton et al.
patent: 2003/0078222 (2003-04-01), Ghildyal et al.
patent: 2004/0022785 (2004-02-01), Clinton et al.
patent: 2004/0052796 (2004-03-01), Clinton et al.
patent: B-64135 (1991-03-01), None
patent: 2055441 (1990-11-01), None
patent: 2042064 (1991-02-01), None
patent: 2187781 (1995-09-01), None
patent: 2260061 (1998-01-01), None
patent: 0412116 (1989-04-01), None
patent: 0494135 (1989-09-01), None
patent: 0 119 528 (1992-05-01), None
patent: 0 491 675 (1992-06-01), None
patent: 0 171 407 (1993-11-01), None
patent: 0 412 116 (1995-11-01), None
patent: 0 494 135 (1996-04-01), None
patent: 0 474 727 (1997-07-01), None
patent: 0 600 744 (1998-03-01), None
patent: 1 006 194 (2000-06-01), None
patent: 1 114 863 (2001-07-01), None
patent: 0 444 181 (2001-10-01), None
patent: 1 304 110 (2003-04-01), None
patent: 1 308 455 (2003-05-01), None
patent: WO 85/03357 (1985-08-01), None
patent: WO 89/10412 (1989-11-01), None
patent: WO 90/14357 (1990-11-01), None
patent: WO 91/02062 (1991-02-01), None
patent: WO 91/05264 (1991-04-01), None
patent: WO 92/14748 (1992-09-01), None
patent: WO 92/20798 (1992-11-01), None
patent: WO 93/14124 (1993-07-01), None
patent: WO 95/25166 (1995-09-01), None
patent: WO 95/30331 (1995-11-01), None
patent: WO 98/23782 (1996-06-01), None
patent: WO 98/02438 (1998-01-01), None
patent: WO 99/19732 (1999-04-01), None
patent: WO 99/39729 (1999-08-01), None
patent: WO 00/27426 (2000-05-01), None
patent: WO0029609 (2000-05-01), None
patent: WO0044403 (2000-08-01), None
patent: WO01/61356 (2001-08-01), None
patent: WO 01/89566 (2001-11-01), None
patent: WO 02/11677 (2002-02-01), None
patent: WO0214470 (2002-02-01), None
patent: WO 02/090991 (2002-11-01), None
patent: WO 03/025141 (2003-03-01), None
patent: WO 03/035843 (2003-05-01), None
patent: WO 03/060071 (2003-07-01), None
patent: WO2005/016966 (2005-02-01), None
Dermer, Bio/Technology, vol. 12, p. 320, Mar. 1994.
Bork, Genome Research, vol. 10, pp. 398-400, 2000.
Bowie et al., Science, vol. 247, pp. 1306-1310, Mar. 1990.
Burgess et al., The Journal of Cell Biology, vol. 111, pp. 2129-2138, Nov. 1990.
Lazar et al., Molecular and Cellular Biology, vol. 8, No. 3, pp. 1247-1252, Mar. 1988.
Dillman et al., Journal of Clinical Oncology, Vo. 12, No. 7, pp. 1497-1515, Jul. 1997.
Xu et al., Int. J. Cancer, vol. 53, pp. 401-408, 1993.
Shepard et al., Journal of Clincal Immunology, vol. 11, No. 3, pp. 117-126, 1991.
Greenspan et al., Nature Biotechnology vol. 7, pp. 936-937, 1999.
Rudikoff et al, (PNAS, USA, 1982, 79: 1979).
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Stancovski, et al (PNAS, USA, 88:8691-8695, 1991).
Lewis, et al (Cancer Immunology Immunotherapy 37: 255-263, 1993).
Strobel, et al (Gynecologic Oncology 73: 362-367, 1999).
“Circulatory HER2 extracellular domain (CCD) levels in Multiple Tumor Xenograft Models of HER-overexpressing Breast Cancer,” Park, J.W., G. Colbern, A. Duijens, J. Baselga, D. Papahadjopoulos, C.C. Benz, UCSF, California; Geraldine Brush Cancer Research Institute, CPMC, SF, CA; Genentech, Inc. So. S.F., CA; Memorial Sloan-Kettering Cancer Center, NY, NY.
Christianson, Tracy A. et al., “NH2-terminally truncated HER-2
eu Protein: Relationship with Shedding of the Extracellular Domain and with Prognostic Factors in Breast Cancer,”Cancer Research 58, 5123-5129, Nov. 15, 1998.
Doherty et al., The HER-2
eu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc. Natl. Acad. Sci. 96:10869-10874, 1999.
Valeron et al., Quantitative analysis of p185HER-2
euprotein in breast cancer and its association with other prognostic factors. Intl. J. Cancer (Pred. Oncol) 74:175-179, 1997.
Zebrecky et al., The extracellular domain of p185
euis released from the surface of human breast carcina cells, SK-BR-3. J. Biol. Chem. 266(3):1716-1720, 1991.
Press et al., Her-2
euexpression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53:4960-4970, 1993.
Reiter et al., A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucl. Acids. Res. 24(20):4050-4056, 1996.
Ross et al., The Her-2
eu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy.Stem Cells, Alphamed Press, Dayton, OH US, vol. 16 No. 6, pp. 413-428, 1998.
Scott et al., A truncated intracellular HER2
eu receptor produced by alternative RNA processing affects growth of human carcinoma cells, Molec. And Cellular Biol. 13(4): 2247-2257, 1993.
Yamamoto et al., Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor, Nature 319:230-234, 1986.
Coussens, et al., Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location withneuOncogene, Science 230:1132-1139, 1985.
Azios et al., Expression of hersta

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

HER-2 binding antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HER-2 binding antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HER-2 binding antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3965112

All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.